NeurogesX's Qutenza faces three month US approval delay
This article was originally published in Scrip
Executive Summary
The US FDA has extended the user fee date of the NDA for NeurogesX's topical anaesthetic Qutenza (capsaicin) for the management of postherpetic neuralgia by three months to November 16th.